In the past years, targeting NAD+ metabolism has been considered for cancer therapy, and most efforts have been focused on nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the NAD+ salvage pathway, whose expression is increased in multiple types of cancer (Garten et al., 2015; Lucena-Cacace et al., 2018; Ohanna et al., 2018; Pylaeva et al., 2019). Here, NAMPT is linked to cancer.